Lixiana provides considerable added benefit for certain patients, says IQWiG

6 November 2015

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether Lixiana (edoxaban) from Japanese drug major Daiichi Sankyo (TYO: 4568) offers an added benefit over the appropriate comparator therapy.

In conclusion, an indication of considerable added benefit compared with vitamin K antagonists was derived for the prevention of stroke and systemic embolism: Stroke, bleeding and severe side effects occurred less frequently under edoxaban. For the second therapeutic indication, suitable analyses were lacking in the company’s dossier, the IQWiG said.

Lixiana has been approved since June 2015 for two therapeutic indications in adults: on the one hand, for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with other risk factors for stroke; on the other, for treatment and prevention of deep vein thrombosis and pulmonary embolism.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK